Per Svenningsson

Oct 3, 2024 | nature.com | Henrik Zetterberg |Per Svenningsson |Fredrik Piehl

AbstractTraumatic brain injury (TBI) is a leading cause of long-term disability across the world. Evidence for the usefulness of imaging and fluid biomarkers to predict outcomes and screen for the need to monitor complications in the acute stage is steadily increasing. Still, many people experience symptoms such as fatigue and cognitive and motor dysfunction in the chronic phase of TBI, where objective assessments for brain injury are lacking.

Aug 15, 2024 | nature.com | Anna Inguanzo |Rosaleena Mohanty |Konstantinos Poulakis |Daniel R. Ferreira |Barbara Segura |Franziska Albrecht | +3 more

AbstractParkinson’s disease (PD) is clinically heterogeneous, which suggests the existence of subtypes; however, there has been no consensus regarding their characteristics. This study included 633 PD individuals across distinct cohorts: unmedicated de novo PD, medicated PD, mild-moderate PD, and a cohort based on diagnostic work-up in clinical practice. Additionally, 233 controls were included.

Apr 28, 2024 | nature.com | Roberta Filograna |Markus Ringnér |Sara Riggare |Per Svenningsson |Michela Barbaro

AbstractLoss-of-function variants in the PRKN gene encoding the ubiquitin E3 ligase PARKIN cause autosomal recessive early-onset Parkinson’s disease (PD). Extensive in vitro and in vivo studies have reported that PARKIN is involved in multiple pathways of mitochondrial quality control, including mitochondrial degradation and biogenesis. However, these findings are surrounded by substantial controversy due to conflicting experimental data.

Mar 4, 2024 | nature.com | Allison Eriksson |Daniel R. Ferreira |Per Svenningsson

AbstractParkinson’s disease (PD) is associated with changes in neural activity in the sensorimotor alpha and beta bands. Using magnetoencephalography (MEG), we investigated the role of spontaneous neuronal activity within the somatosensory cortex in a large cohort of early- to mid-stage PD patients (N = 78) on Parkinsonian medication and age- and sex-matched healthy controls (N = 60) using source reconstructed resting-state MEG.

Jul 26, 2023 | nature.com | Dominika Luptáková |Yachao He |Theodosia Vallianatou |Per Svenningsson |Erwan Bezard |Patrik Bjärterot

AbstractMetabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to the neurotoxin MPP+ in the brain causes permanent Parkinson’s disease-like symptoms by destroying dopaminergic neurons in the pars compacta of the substantia nigra in humans and non-human primates. However, the complete molecular pathology underlying MPTP-induced parkinsonism remains poorly understood.